Advertisement St Jude awarded US patent for depression therapy - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

St Jude awarded US patent for depression therapy

St Jude Medical has received a patent from the US Patent and Trademark Office for treating depression using neurostimulation therapy in an area of the brain known as Brodmann Area 25.

Brodmann Area 25 is a structure within the subcollosal gyrus region of the brain. It is the focus of the St Jude Medical Broaden study, which is evaluating whether deep brain stimulation therapy can help people who suffer from major depressive disorder, a severe form of depression.

Chris Chavez, president of St Jude Medical’s ANS division, said: “This patent is a cornerstone in developing our approach to deep brain stimulation for depression, which is the leading cause of disability in the US among illnesses. The Broaden study provides hope for a meaningful new therapy to the millions of patients still seeking treatment for their severe depression.”